Concepedia

T.B. Powles

TP

Statistics

Publications

8

Citations

504

H-Index

8

Active since

2018

Affiliations

Queen Mary University of London(Current)

Dana-Farber Cancer Institute

Institut Gustave Roussy

University College London

Fox Chase Cancer Center

T.B. Powles is an author at Queen Mary University of London specializing in oncology, renal cell carcinoma, and kidney cancer.

Publications per year

2018–2024

8

Publications

8

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

, , +16

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Brian I. Rini, Mahrukh Huseni, Michael B. Atkins et al. · Annals of Oncology · 2018 · 72 citations

, , +15

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

Laurence Albigès, Brian I. Rini, Katriina Peltola et al. · Annals of Oncology · 2023 · 53 citations · Full text

, , +10

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Robert J. Motzer, Nizar M. Tannir, David F. McDermott et al. · Annals of Oncology · 2021 · 37 citations

, , +12

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto et al. · Annals of Oncology · 2020 · 25 citations

, , +12

1–5 of 8